Sec Form 3 Filing - Helwig Steven @ Radius Health, Inc. - 2021-08-24

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Helwig Steven 2. Issuer Name and Ticker or Trading Symbol Radius Health, Inc. [ RDUS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Principal Financial Officer (Last) (First) (Middle) C/O RADIUS HEALTH, INC., 22 BOSTON WHARF ROAD, 7TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 08/24/2021 (Street) BOSTON, MA02210 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 15,704 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 63.34 ( 2 ) 08/26/2025 Common Stock 10,750 D Stock Option (Right to Buy) $ 19.18 ( 3 ) 02/22/2029 Common Stock 3,500 D Stock Option (Right to Buy) $ 20.25 ( 4 ) 03/02/2030 Common Stock 3,500 D Stock Option (Right to Buy) $ 21.66 ( 5 ) 01/20/2031 Common Stock 12,250 D Stock Option (Right to Buy) $ 18.6 ( 6 ) 02/22/2031 Common Stock 20,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Helwig Steven C/O RADIUS HEALTH, INC. 22 BOSTON WHARF ROAD, 7TH FLOOR BOSTON, MA02210 Principal Financial Officer Signatures /s/ Averi Price, as attorney-in-fact 08/26/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The amount reflected includes 375 restricted stock units awarded under the 2011 Equity Incentive Plan and 4,542 restricted stock units awarded under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The shares underlying the restricted stock units vest as follows: (a) 375 of such shares shall vest on February 13, 2022; (b) 1,000 of such shares shall vest as to 50% on February 22, 2022 and 50% on February 22, 2023; (c) 1,667 of such shares shall vest as to 50% on March 2, 2022 and 50% on March 2, 2023; and (d) 1,875 of such shares shall vest as to 33.33% on November 9, 2021 and as to 33.33% annually thereafter over the following two years on November 9 of each year. ( 2 )The shares subject to this stock option are fully vested and exercisable. ( 3 )25% of the shares subject to this stock option vested on February 22, 2020; and the remaining shares have vested or shall vest in substantially equal monthly installments over 36 months thereafter. ( 4 )25% of the shares are subject to this stock option vested on March 2, 2021; and the remaining shares have vested or shall vest in substantially equal monthly installments over 36 months thereafter. ( 5 )25% of the shares subject to this stock option shall vest on January 20, 2022; and the remaining shares shall vest in substantially equal monthly installments over 36 months thereafter. ( 6 )25% of the shares subject to this stock option shall vest on February 22, 2022; and the remaining shares shall vest in substantially equal monthly installments over 36 months thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.